Johnson & Johnson is currently facing a proposed class action lawsuit that seeks damages and medical monitoring for women who have been diagnosed with cancer or may develop it in the future.

According to Reuters, the lawsuit claims that the use of the company's baby powder and other talc products is responsible for these health issues.

Johnson & Johnson Faces New Class Action Lawsuit

A new lawsuit was filed on Monday (June 17) in a New Jersey federal court, marking a significant development.

This particular case is the first of its kind to request medical monitoring for talc users, which involves regular testing to detect cancer at an early stage.

The potential class could encompass a significant number of women, excluding those who have already filed personal injury lawsuits against J&J for their talc products, alleging the presence of cancer-causing asbestos.

J&J asserts that its talc is safe, free of asbestos, and does not contribute to the development of cancer.

The law firms involved in the new case strongly oppose J&J's suggestion to resolve almost all talc claims against it for $6.48 billion by means of a prepackaged bankruptcy.

Several companies are also actively pursuing a separate class action to obtain a court order that would prevent the bankruptcy from proceeding.

The bankruptcy proposal requires the backing of 75% of talc claimants, and the voting period will conclude on July 26 after three months.

READ NEXT: Florida McDonald's Employee Arrested for Shooting at Drive-Through Customers After Dispute 

Johnson & Johnson Agrees to Pay Millions in Opioid Lawsuit

Meanwhile, Johnson & Johnson reached a settlement and agreed to pay $123.34 million following a lawsuit filed by Attorney General Bob Ferguson in 2020, which accused them of contributing to the opioid crisis.

On Tuesday (June 18), Attorney General Bob Ferguson announced that a settlement had been reached, effectively resolving the case without the need for a court trial.

The funds will be fairly allocated to state and local governments, in accordance with the state's Opioid Response Plan, and must be utilized to address the opioid crisis.

READ MORE: Rare Flu Variant in US Shows Resistance to Common Antiviral, CDC Warns